4//SEC Filing
Galdes Alphonse 4
Accession 0001127602-21-006267
CIK 0000875045other
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 4:54 PM ET
Size
27.3 KB
Accession
0001127602-21-006267
Insider Transaction Report
Form 4
BIOGEN INC.BIIB
Galdes Alphonse
EVP Pharmaceutical Oper & Tech
Transactions
- Exercise/Conversion
Restricted Stock Unit
2021-02-12−327→ 1,235 totalExercise: $0.00Exp: 2022-02-12→ Common Stock (327 underlying) - Other
Restricted Stock Unit
2021-02-12−1,298→ 4,522 totalExercise: $0.00Exp: 2023-02-12→ Common Stock (1,298 underlying) - Other
Restricted Stock Unit
2021-02-12−322→ 0 totalExercise: $0.00Exp: 2021-02-12→ Common Stock (322 underlying) - Exercise/Conversion
Restricted Stock Unit
2021-02-12−960→ 5,820 totalExercise: $0.00Exp: 2023-02-12→ Common Stock (960 underlying) - Tax Payment
Common Stock
2021-02-12$278.03/sh−253$70,342→ 3,192.229 total - Exercise/Conversion
Common Stock
2021-02-12+286→ 3,478.229 total - Exercise/Conversion
Common Stock
2021-02-12+327→ 3,805.229 total - Exercise/Conversion
Common Stock
2021-02-12+960→ 4,765.229 total - Tax Payment
Common Stock
2021-02-12$278.03/sh−84$23,355→ 4,681.229 total - Tax Payment
Common Stock
2021-02-12$278.03/sh−96$26,691→ 4,585.229 total - Tax Payment
Common Stock
2021-02-12$278.03/sh−282$78,404→ 4,303.229 total - Exercise/Conversion
Restricted Stock Unit
2021-02-12−286→ 322 totalExercise: $0.00Exp: 2021-02-12→ Common Stock (286 underlying) - Other
Restricted Stock Unit
2021-02-12−451→ 784 totalExercise: $0.00Exp: 2022-02-12→ Common Stock (451 underlying)
Holdings
- 969.366(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]Represents shares withheld to satisfy the withholding tax liability due upon the vesting of shares, as previously disclosed by reporting person on January 29, 2021.
- [F2]The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
- [F3]This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
Documents
Issuer
BIOGEN INC.
CIK 0000875045
Entity typeother
Related Parties
1- filerCIK 0001789471
Filing Metadata
- Form type
- 4
- Filed
- Feb 16, 7:00 PM ET
- Accepted
- Feb 17, 4:54 PM ET
- Size
- 27.3 KB